Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions.
Ten years after the first description of activating mutations in the thyroid stimulating hormone receptor (TSHR) gene in sporadic autonomous hyperfunctioning thyroid adenomas, there is general agreement in assigning a major pathogenic role of this genetic abnormality, acting via the constitutive activation of the cAMP pathway, in both the growth and functional characteristic of these tumours. From the beginning, however, the pathophysiological and clinical relevance of somatic TSHR mutations has been debated and some arguments still exist against a fully causative role of these mutations and the practical value of detecting these mutations for the diagnosis, treatment and prognosis of thyroid hot nodules. Some major issues will be examined herein, including (a) the frequency of TSHR alterations in various reports showing that the genetic abnormality underlying the pathogenesis of a substantial subset of thyroid tumours has yet to be identified; (b) the limitations of the present experimental models, which suggest greater caution in the interpretation of in vitro results; (c) the still unresolved question of absence of genotype-phenotype correlation. Clarification of these issues may hopefully provide new and useful tools for improving the clinical management of this disease.
Arturi
F
F
Dipartimento di Medicina Sperimentale e Clinica, University of Catanzaro, Catanzaro, Italy.
Scarpelli
D
D
Coco
A
A
Sacco
R
R
Bruno
R
R
Filetti
S
S
Russo
D
D
D000236:Adenoma / Q000235:genetics* / Q000503:physiopathology*; D006801:Humans; D009154:Mutation; D011989:Receptors, Thyrotropin / Q000235:genetics*; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000503:physiopathology*; D016606:Thyroid Nodule / Q000235:genetics / Q000503:physiopathology
D011989:Receptors, Thyrotropin